Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Triggering receptor expressed on myeloid cells like 3, pseudogene (TREML3P), also known as TREM like transcript 3 (TLT3), is a human pseudogene located in a gene cluster on chromosome 6 with structurally related genes such as TREM1 and TREM2. In mice, TREM-3 is a functional receptor involved in the immune response, but in humans, TREML3P lacks known protein-coding ability—that is, it does not encode a functional protein product and has no known biological or therapeutic role. Therefore, it is not considered a therapeutic target in humans[4][1].\n\nClarifications:\n- TREML3P is frequently confused with related functional receptors (like TREM-1, TREM-2, or murine TREM-3) that have established biological and therapeutic significance, but TREML3P itself is nonfunctional in humans and should not be considered a drug target or biomarker[4][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Triggering receptor expressed on myeloid cells like 3, pseudogene (TREML3P).